Abstract
High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.
Original language | English |
---|---|
Article number | 107502 |
Journal | Cell Reports |
Volume | 31 |
Issue number | 2 |
DOIs | |
State | Published - 14 Apr 2020 |
Externally published | Yes |
Keywords
- R0 resection
- copy number
- genomics
- immune monitoring
- multi-omics
- mutation
- neoadjuvant chemotherapy
- ovarian cancer
- proteome
- transcriptome
Access to Document
Fingerprint
Dive into the research topics of 'Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. / Lee, Sanghoon; Zhao, Li; Rojas, Christine et al.
In: Cell Reports, Vol. 31, No. 2, 107502, 14.04.2020.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
AU - Lee, Sanghoon
AU - Zhao, Li
AU - Rojas, Christine
AU - Bateman, Nicholas W.
AU - Yao, Hui
AU - Lara, Olivia D.
AU - Celestino, Joseph
AU - Morgan, Margaret B.
AU - Nguyen, Tri V.
AU - Conrads, Kelly A.
AU - Rangel, Kelly M.
AU - Dood, Robert L.
AU - Hajek, Richard A.
AU - Fawcett, Gloria L.
AU - Chu, Randy A.
AU - Wilson, Katlin
AU - Loffredo, Jeremy L.
AU - Viollet, Coralie
AU - Jazaeri, Amir A.
AU - Dalgard, Clifton L.
AU - Mao, Xizeng
AU - Song, Xingzhi
AU - Zhou, Ming
AU - Hood, Brian L.
AU - Banskota, Nirad
AU - Wilkerson, Matthew D.
AU - Te, Jerez
AU - Soltis, Anthony R.
AU - Roman, Kristin
AU - Dunn, Andrew
AU - Cordover, David
AU - Eterovic, Agda Karina
AU - Liu, Jinsong
AU - Burks, Jared K.
AU - Baggerly, Keith A.
AU - Fleming, Nicole D.
AU - Lu, Karen H.
AU - Westin, Shannon N.
AU - Coleman, Robert L.
AU - Mills, Gordon B.
AU - Casablanca, Yovanni
AU - Zhang, Jianhua
AU - Conrads, Thomas P.
AU - Maxwell, George L.
AU - Futreal, P. Andrew
AU - Sood, Anil K.
N1 - Funding Information: We thank S. Patterson (Department of Scientific Publications, MD Anderson Cancer Center, Houston, TX) for editorial assistance. We would like to acknowledge the MD Anderson Functional Proteomics Reverse Phase Protein Array Core for help with the RPPA assay, the MD Anderson Biospecimen Extraction Resource for extraction of genomic DNAs, the MD Anderson Research Histology Core Laboratory for IHC assay, and the Collaborative Health Initiative Research Program Laboratory Core for whole-genome sequencing library preparation and profiling. This work was supported in part by the MD Anderson Ovarian Cancer Moon Shot Program; National Institutes of Health (NIH) grants P50CA217685, R35CA209904, and P30CA016672 (used the Clinical Trials Office, Functional Proteomics Reverse Phase Protein Array Core, Research Histology Core Laboratory, and Cancer Genomics Laboratory); and the MD Anderson Center for Translational and Public Health Genomics (used the Biospecimen Extraction Resource). S.N.W. is supported by the Andrew Sabin Family Fellowship and the GOG Foundation Scholar Investigator Award. A.K.S. is supported by the American Cancer Society Research Professor Award and the Frank McGraw Memorial Chair in Cancer Research. O.D.L. is supported by an NIH institutional training grant (5T32CA009599). G.B.M. is supported by a kind gift from the Adelson Research Foundation; NIH grants U01CA217842, P50CA217685, P50CA098258,U24CA210950, and U54HG008100; Susan G. Komen grant SAC110052; Breast Cancer Research Foundation grant BCRF-17-108; the Ovarian Cancer Research Foundation; and Cancer Prevention and Research Institute of Texas grant RP170640. C.R. N.W.B. K.A.C. K.W. J.L.L. B.L.H. Y.C. T.P.C. and G.L.M. are supported by the Uniformed Services University of the Health Sciences award to the Gynecologic Cancer Center of Excellence (HU0001-16-2-0006), administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine. A.K.S. and P.A.F. supervised the study. S.L. Y.C. T.P.C. G.L.M. P.A.F. and A.K.S. conceived and designed the study. S.L. took the lead in writing the manuscript. S.L. L.Z. N.W.B. H.Y. O.D.L. T.P.C. and A.K.S. wrote the manuscript. S.L. L.Z. N.W.B. M.B.M. G.L.F. R.A.C. X.M. X.S. A.K.E. J.Z. T.P.C. P.A.F. and A.K.S. analyzed, managed, and interpreted the sequencing data. L.Z. C.V. C.L.D. N.B. M.D.W. J.T. A.R.S. J.Z. and P.A.F. analyzed and managed the WGS data. S.L. L.Z. J.Z. P.A.F. and A.K.S. interpreted the WGS data. S.L. L.Z. H.Y. J.Z. P.A.F. and A.K.S. analyzed and interpreted the RPPA data. S.L. and J.L. analyzed and interpreted the IHC data. K.R, A.D. and D.C performed the immune assessment. S.L. O.D.L. K.R. A.D. D.C. J.K.B. J.L. and A.K.S. analyzed and interpreted the immune assessment data. S.L. L.Z. C.R. N.W.B. K.A.C. K.W. J.L. M.Z. B.L.H. T.P.C. and A.K.S. analyzed and interpreted the LC-MS/MS data. S.L. J.C. T.V.N. K.M.R. R.L.D. A.A.J. J.L. K.A.B. N.D.F. K.H.L. S.N.W. R.L.C. G.B.M. and A.K.S. contributed to clinical samples and data acquisition. All authors read and approved the final manuscript. A.A.J. consults with Roche/Genentech, Aravive, and Almac Group; has research funding from AstraZeneca, Pfizer, Bristol-Myers Squibb, Immatics, Iovance Biotherapeutics; honoraria from Gerson Lehrman Group; and travel support from AstraZeneca and MedImmune. K.R. A.D. and D.C. are employees of Akoya Biosciences. N.D.F. consults with Tesaro. S.N.W. has clinical research grants from AstraZeneca, ArQule, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, NCCN, Novartis, Roche/Genentech, and Tesaro and consults with AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, Takeda, and Tesaro. R.L.C. has clinical research grants from AstraZeneca, Merck, Clovis Oncology, Genmab, Roche/Genentech, Janssen, V Foundation, and Gateway for Cancer Research and consults with AstraZeneca, Merck, Tesaro, Medivation, Clovis Oncology, Genmab, GamaMabs, Agenus, Regeneron, OncoQuest, OncoSec, Roche/Genentech, and Janssen. G.B.M. consults with AstraZeneca, ImmunoMet, Ionis, Nuevolution, PDX Phamaceuticals, SignalChem, Symphogen, and Tarveda Therapeutics; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Captial, and Tarveda Therapeutics; sponsored research from AstraZeneca, ImmunoMet, Pfizer, NanoString, and Tesaro and travel support from Chrysallis BioTherapeutics; and has licensed technology to NanoString and Myriad Genetics. Y.C.?s spouse owns stock in Celsion. T.P.C. consults with Thermo Fisher Scientific and has research funding from AbbVie. G.L.M. consults with Merck, Kiyatek, Renovia, and Tesaro and has research funding from Merck. A.K.S. consults with Merck and Kiyatec, has research funding from M-Trap, and is a shareholder of Bio-Path Holdings. All other authors declare no competing interests. Funding Information: We thank S. Patterson (Department of Scientific Publications, MD Anderson Cancer Center, Houston, TX) for editorial assistance. We would like to acknowledge the MD Anderson Functional Proteomics Reverse Phase Protein Array Core for help with the RPPA assay, the MD Anderson Biospecimen Extraction Resource for extraction of genomic DNAs, the MD Anderson Research Histology Core Laboratory for IHC assay, and the Collaborative Health Initiative Research Program Laboratory Core for whole-genome sequencing library preparation and profiling. This work was supported in part by the MD Anderson Ovarian Cancer Moon Shot Program ; National Institutes of Health (NIH) grants P50CA217685 , R35CA209904 , and P30CA016672 (used the Clinical Trials Office, Functional Proteomics Reverse Phase Protein Array Core, Research Histology Core Laboratory, and Cancer Genomics Laboratory); and the MD Anderson Center for Translational and Public Health Genomics (used the Biospecimen Extraction Resource). S.N.W. is supported by the Andrew Sabin Family Fellowship and the GOG Foundation Scholar Investigator Award . A.K.S. is supported by the American Cancer Society Research Professor Award and the Frank McGraw Memorial Chair in Cancer Research . O.D.L. is supported by an NIH institutional training grant ( 5T32CA009599 ). G.B.M. is supported by a kind gift from the Adelson Research Foundation ; NIH grants U01CA217842 , P50CA217685 , P50CA098258 , U24CA210950 , and U54HG008100 ; Susan G. Komen grant SAC110052 ; Breast Cancer Research Foundation grant BCRF-17-108 ; the Ovarian Cancer Research Foundation ; and Cancer Prevention and Research Institute of Texas grant RP170640 . C.R., N.W.B., K.A.C., K.W., J.L.L., B.L.H., Y.C., T.P.C., and G.L.M. are supported by the Uniformed Services University of the Health Sciences award to the Gynecologic Cancer Center of Excellence ( HU0001-16-2-0006 ), administered by the Henry M. Jackson Foundation for the Advancement of Military Medicine . Publisher Copyright: © 2020 The Author(s)
PY - 2020/4/14
Y1 - 2020/4/14
N2 - High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.
AB - High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.
KW - R0 resection
KW - copy number
KW - genomics
KW - immune monitoring
KW - multi-omics
KW - mutation
KW - neoadjuvant chemotherapy
KW - ovarian cancer
KW - proteome
KW - transcriptome
UR - http://www.scopus.com/inward/record.url?scp=85083004505&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2020.03.066
DO - 10.1016/j.celrep.2020.03.066
M3 - Article
C2 - 32294438
AN - SCOPUS:85083004505
SN - 2211-1247
VL - 31
JO - Cell Reports
JF - Cell Reports
IS - 2
M1 - 107502
ER -